{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/diagnosis/diagnosis-in-adults/","result":{"pageContext":{"chapter":{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults","depth":2,"htmlHeader":"<!-- begin field 0db7becd-3b2d-4e38-9d08-499ef7a26fd6 --><h2>When should I suspect type 2 diabetes in an adult?</h2><!-- end field 0db7becd-3b2d-4e38-9d08-499ef7a26fd6 -->","summary":"","htmlStringContent":"<!-- begin item 7a7a9c89-036c-4a3b-b036-4876e4a5c9a2 --><!-- begin field d0309cfa-1853-453d-a8a0-e8ebcf5ffc06 --><p><strong>Suspect a diagnosis of type 2 diabetes if an adult presents with persistent hyperglycaemia that may be accompanied by clinical features.</strong></p><ul><li>Possible clinical features of type 2 diabetes include:<ul><li>Symptoms such as polydipsia, polyuria, blurred vision, unexplained weight loss, recurrent infections, and tiredness. Note: these may be mild or absent.</li><li>Signs such as acanthosis nigricans (a skin condition causing dark pigmentation of skin folds, typically the axillae, groin, and neck), which suggests insulin resistance.</li><li>The presence of <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/background-information/risk-factors/\">risk factors</a>.</li></ul></li><li>Persistent hyperglycaemia is defined as:<ul><li>HbA1c of 48 mmol/mol (6.5%) or more.</li><li>Fasting plasma glucose level of 7.0 mmol/L or more.</li><li>Random plasma glucose of 11.1 mmol/L or more in the presence of symptoms or signs of diabetes.<ul><li>If the person is symptomatic, a single abnormal HbA1c or fasting plasma glucose level can be used, although repeat testing is sensible to confirm the diagnosis.</li><li>If the person is asymptomatic, do not diagnose diabetes on the basis of a single abnormal HbA1c or plasma glucose result. Arrange repeat testing, preferably with the same test, to confirm the diagnosis. If the repeat test result is normal, arrange to monitor the person for the development of diabetes, the frequency depending on clinical judgement.</li></ul></li><li>Note: be aware that severe hyperglycaemia in people with acute infection, trauma, circulatory or other stress may be transitory and is not diagnostic of diabetes.</li></ul></li><li><strong>If the HbA1c result is <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/diagnosis/diagnosis-in-adults/#interpreting-hba1c-results\">difficult to interpret</a>:</strong><ul><li>Diagnose type 2 diabetes on the basis of a fasting plasma glucose level of 7.0 mmol/L or more.<ul><li>If there is uncertainty about the use of HbA1c in the diagnosis or monitoring of type 2 diabetes, seek advice from the specialist diabetes team or clinical biochemistry.</li></ul></li></ul></li><li><strong>When confirming the diagnosis, be aware type 2 diabetes is more likely if there are:</strong><ul><li>No additional features of type 1 diabetes (such as rapid onset, often in childhood, insulin dependence, or ketoacidosis). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> for more information.</li><li>No clinical features of <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/background-information/definition/\">other types of diabetes</a>, such as monogenic diabetes or diabetes secondary to another condition or disease.</li></ul></li></ul><!-- end field d0309cfa-1853-453d-a8a0-e8ebcf5ffc06 --><!-- end item 7a7a9c89-036c-4a3b-b036-4876e4a5c9a2 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"e02168c6-641d-52f0-894e-9847f3427bc8","slug":"interpreting-hba1c-results","fullItemName":"Interpreting HbA1c results","depth":3,"htmlHeader":"<!-- begin field 4397ebe6-ed8d-4034-ace4-2653af003d41 --><h3>Interpreting HbA1c results</h3><!-- end field 4397ebe6-ed8d-4034-ace4-2653af003d41 -->","summary":null,"htmlStringContent":"<!-- begin item 429cb906-a91f-4051-9fc0-4a5953a90dbb --><!-- begin field 87525273-f600-4a6f-be5a-7ff9262239cc --><ul><li><strong>HbA1c should not be used to diagnose diabetes mellitus </strong><strong>in the following groups:</strong><ul><li>Children and young people less than 18 years of age. </li><li>Pregnant women or women who are 2 months postpartum. </li><li>People with symptoms of diabetes for less than 2 months. </li><li>People at high diabetes risk who are acutely ill.</li><li>People taking medication that may cause hyperglycaemia (for example long-term corticosteroid treatment). </li><li>People with acute pancreatic damage, including pancreatic surgery.</li><li>People with end-stage renal disease (ESRD). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for more information.</li><li>People with HIV infection. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hiv-infection-aids/\">HIV infection and AIDS</a> for more information.</li></ul></li><li><strong>HbA1c should be interpreted with caution</strong><strong> in people with abnormal red blood cell turnover or abnormal haemoglobin type:</strong> <ul><li>Abnormal haemoglobin, such as haemoglobinopathy.</li><li>Severe anaemia (any cause). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-iron-deficiency/\">Anaemia - iron deficiency</a> and <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-b12-folate-deficiency/\">Anaemia - B12 and folate deficiency</a> for more information.</li><li>Altered red cell lifespan (for example post-splenectomy). </li><li>A recent blood transfusion.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Kilpatrick, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Davies, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Milne, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>]</p><!-- end field 87525273-f600-4a6f-be5a-7ff9262239cc --><!-- end item 429cb906-a91f-4051-9fc0-4a5953a90dbb -->","subChapters":[]},{"id":"eb34712f-061b-5f38-b37b-672bf08fa2af","slug":"basis-for-recommendation-544","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field f2ac5483-b50a-4982-be18-785aa521421b --><h3>Basis for recommendation</h3><!-- end field f2ac5483-b50a-4982-be18-785aa521421b -->","summary":null,"htmlStringContent":"<!-- begin item 54497a06-132d-43c1-9e4a-bbf0f0e6c6dc --><!-- begin field 9a0b553a-9de9-4c38-b4bc-b786f164f536 --><p>The recommendations on diagnosis in adults are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Type 2 diabetes in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>], the World Health Organization (WHO) publications <em>Classification of diabetes mellitus 2019</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2019</a>] and <em>Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2011</a>], the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) consensus report <em>Management of hyperglycaemia in type 2 diabetes, 2018</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Davies, 2018</a>], the International Society for Pediatric and Adolescent Diabetes (ISPAD) clinical practice consensus guidelines 2018 <em>Definition, epidemiology, and classification of diabetes in children and adolescents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Mayer-Davis, 2018</a>], and expert opinion in review articles on using HbA1c in diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Kilpatrick, 2014</a>] and on diabetic reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Milne, 2020</a>].</p><h4>When to suspect type 2 diabetes</h4><ul><li>The information on possible presenting symptoms of type 2 diabetes is based on the ADA/EASD consensus report [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Davies, 2018</a>]. The information on the sign of acanthosis nigricans is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>].</li><li>The information on the presence of risk factors is based on the WHO publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2019</a>] and the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>].</li><li>The information on the definition of persistent hyperglycaemia is based on the WHO publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2019</a>].</li><li>The recommendation to repeat the HbA1c or plasma glucose level if the person is asymptomatic is based on the WHO publication, which advises this should be carried out as soon as possible on a subsequent day to confirm the diagnosis of diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2019</a>]. The recommendation to monitor the person depending on clinical judgement if repeat testing is normal is pragmatic, based on what CKS considers to be good clinical practice.</li><li>The information that transient hyperglycaemia in the context of acute illness or stress is not diagnostic of diabetes is extrapolated from the paediatric ISPAD clinical practice consensus guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Mayer-Davis, 2018</a>]. </li></ul><h4>Interpreting HbA1c results</h4><ul><li>Expert opinion in a review article notes various advantages in the use of HbA1c to diagnose diabetes, including no requirement for the person to fast or perform an oral glucose tolerance test. In addition, it assesses blood glucose control over the preceding 8–12 weeks and there is lower biological variability with HbA1c than with fasting glucose or 2-hour post-glucose load concentration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Kilpatrick, 2014</a>].</li><li>The information on clinical circumstances when HbA1c results should not be used or interpreted with caution is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>], the WHO publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2011</a>], the ADA/EASD consensus report [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Davies, 2018</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Kilpatrick, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Milne, 2020</a>].<ul><li>The WHO publication recommends HbA1c as a diagnostic test for diabetes, providing there are no conditions present that preclude its accurate measurement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">WHO, 2011</a>]. </li></ul></li><li>The recommendation to seek specialist advice if there is uncertainty about the use of HbA1c in diagnosis or monitoring is extrapolated from the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h4>Factors increasing the likelihood of type 2 diabetes</h4><ul><li>The information that a diagnosis of type 2 diabetes is more likely if there are no features of type 1 diabetes or other types or secondary causes of diabetes is extrapolated from the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>].</li></ul><!-- end field 9a0b553a-9de9-4c38-b4bc-b786f164f536 --><!-- end item 54497a06-132d-43c1-9e4a-bbf0f0e6c6dc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}